Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

ClinicalTrials.gov ID: NCT02675829

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02675829. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 6:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to find out what effects, a drug called ado-trastuzumab emtansine has on the patient and their cancer which is thought to be controlled by the abnormal HER2 gene.

Study identification

NCT ID
NCT02675829
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
131 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 16, 2016 (Actual)
Primary completion
Sep 4, 2026 (Actual)
Completion
Sep 4, 2026 (Actual)
Last update posted
Sep 9, 2026

2016 – 2026

United States locations

U.S. sites
7
U.S. states
2
U.S. cities
7
Facility City State ZIP Site status
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge New Jersey 07920 —
Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown New Jersey 07748 —
Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale New Jersey 07645 —
Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities) Commack New York 11725 —
Memorial Sloan Kettering Westchester (Limited Protocol Activities) Harrison New York 10604 —
Memorial Sloan Kettering Cancer Center New York New York 10065 —
Memorial Sloan Kettering Nassau (Limited Protocol Activities) Uniondale New York 11553 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02675829, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 9, 2026 · Synced Nov 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.